Skip to main content
BMC Cardiovascular Disorders logoLink to BMC Cardiovascular Disorders
. 2024 Mar 25;24:179. doi: 10.1186/s12872-024-03847-6

A nomogram model for predicting intramyocardial hemorrhage post-PCI based on SYNTAX score and clinical features

Yin-shuang Yang 1,#, De-yang Xi 1,#, Yang Duan 2, Miao Yu 3, Kai Liu 3, Yan-kai Meng 3, Chun-feng Hu 3, Shu-guang Han 1,3,, Kai Xu 1,3,
PMCID: PMC10964630  PMID: 38528469

Abstract

Objective

The aim of this study is to develop a nomogram model for predicting the occurrence of intramyocardial hemorrhage (IMH) in patients with Acute Myocardial Infarction (AMI) following Percutaneous Coronary Intervention (PCI). The model is constructed utilizing clinical data and the SYNTAX Score (SS), and its predictive value is thoroughly evaluated.

Methods

A retrospective study was conducted, including 216 patients with AMI who underwent Cardiac Magnetic Resonance (CMR) within a week post-PCI. Clinical data were collected for all patients, and their SS were calculated based on coronary angiography results. Based on the presence or absence of IMH as indicated by CMR, patients were categorized into two groups: the IMH group (109 patients) and the non-IMH group (107 patients). The patients were randomly divided in a 7:3 ratio into a training set (151 patients) and a validation set (65 patients). A nomogram model was constructed using univariate and multivariate logistic regression analyses. The predictive capability of the model was assessed using Receiver Operating Characteristic (ROC) curve analysis, comparing the predictive value based on the area under the ROC curve (AUC).

Results

In the training set, IMH post-PCI was observed in 78 AMI patients on CMR, while 73 did not show IMH. Variables with a significance level of P < 0.05 were screened using univariate logistic regression analysis. Twelve indicators were selected for multivariate logistic regression analysis: heart rate, diastolic blood pressure, ST segment elevation on electrocardiogram, culprit vessel, symptom onset to reperfusion time, C-reactive protein, aspartate aminotransferase, lactate dehydrogenase, creatine kinase, creatine kinase-MB, high-sensitivity troponin T (HS-TnT), and SYNTAX Score. Based on multivariate logistic regression results, two independent predictive factors were identified: HS-TnT (Odds Ratio [OR] = 1.61, 95% Confidence Interval [CI]: 1.21–2.25, P = 0.003) and SS (OR = 2.54, 95% CI: 1.42–4.90, P = 0.003). Consequently, a nomogram model was constructed based on these findings. The AUC of the nomogram model in the training set was 0.893 (95% CI: 0.840–0.946), and in the validation set, it was 0.910 (95% CI: 0.823–0.970). Good consistency and accuracy of the model were demonstrated by calibration and decision curve analysis.

Conclusion

The nomogram model, constructed utilizing HS-TnT and SS, demonstrates accurate predictive capability for the risk of IMH post-PCI in patients with AMI. This model offers significant guidance and theoretical support for the clinical diagnosis and treatment of these patients.

Keywords: Acute myocardial infarction, Cardiac magnetic resonance, SYNTAX score, Nomogram

Introduction

Acute Myocardial Infarction (AMI) results from the rupture or erosion of atherosclerotic plaques in coronary arteries, causing acute constriction or obstruction of vessels and leading to sudden myocardial ischemia and necrosis [1, 2]. AMI, encompassing ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), is a critical cardiac event. STEMI may also present initially with acute heart failure [3]. Globally, ischemic heart disease stands as the foremost burden on health, as measured by disability-adjusted life years [4, 5]. Currently, Percutaneous Coronary Intervention (PCI), as endorsed by guidelines, has contributed to a reduction in mortality among AMI patients [6]. Nevertheless, despite effective epicardial reperfusion, a substantial number of AMI patients experience chronic heart failure due to poor microvascular function and inadequate recovery of myocardial perfusion, known as ‘no-reflow’ or microvascular obstruction (MVO) [7]. MVO can result in elevated intramyocardial pressure, leading to capillary rupture and Intramyocardial Hemorrhage (IMH) [8]. This hemorrhage further compromises myocardial tissue, exacerbating myocardial injury [9]. The ESC’s fourth universal definition of myocardial infarction guidelines provides a detailed categorization of myocardial infarction types based on underlying causes. This classification aids in tailoring treatment approaches according to the specific type of myocardial infarction, which can significantly impact patient prognosis [10].

Cardiac Magnetic Resonance (CMR), acknowledged as the gold standard for non-invasive cardiac structure and function assessment [11], can identify MVO and IMH using delayed gadolinium enhancement and T2* sequences, respectively [12]. The SYNTAX Score (SS) serves as a method to gauge the severity of coronary artery disease [13]. SS quantitatively assesses the complexity of coronary artery lesions based on anatomical characteristics such as lesion location, severity, morphology, bifurcation, and vascular calcification, effectively predicting the occurrence of adverse cardiovascular and cerebrovascular events. Studies have established a correlation between a higher SS, the extent of myocardial injury, and the Myocardial Salvage Index (MSI) post-PCI in AMI patients [14]. A higher SS is associated with a larger myocardial infarction (MI) area and a lower MSI, potentially indicating more severe myocardial reperfusion hemorrhage and unfavorable cardiac remodeling [15]. SS is an independent predictor of major adverse cardiac events (MACE) and three-year mortality post-direct PCI [16, 17]. Currently, several risk models and scoring systems have been developed to predict bleeding events following percutaneous coronary intervention (PCI) [1820], such as the PRECISE-DAPT score. These models primarily focus on the bleeding risk in patients on antiplatelet therapy post-PCI, particularly significant bleeding events. However, no studies have yet explored the risk of intramyocardial hemorrhage in patients with myocardial infarction after PCI. Besides, the utilization of SS in predicting the occurrence of IMH post-PCI in AMI patients has not been reported to date. This study aims to construct a nomogram model using clinical data and SS to predict the occurrence of IMH in patients with AMI after PCI.

Methods

Study population

This retrospective study enrolled 216 patients with AMI who underwent emergency PCI at the Affiliated Hospital of Xuzhou Medical University between September 2019 and June 2023, and were randomly divided into a training set and a validation set at a ratio of 7:3. The sample size met the principle of 10 Events Per Variable (EPV). Inclusion criteria were: (1) AMI diagnosis following the European Society of Cardiology guidelines [6]; (2) First-time myocardial infarction patients with confirmed Infarct-Related Artery (IRA) through Coronary Angiography (CAG) post Percutaneous Transluminal Coronary Angioplasty (PTCA) who successfully underwent PCI; (3) Adequate angiographic image quality for SYNTAX Score (SS) calculation; (4) Underwent Cardiac Magnetic Resonance (CMR) within one week post-surgery with satisfactory image quality. Exclusion criteria were: (1) History of myocardial infarction; (2) Previous PCI or coronary artery bypass grafting; (3) Contraindications for late gadolinium enhancement (LGE)-CMR or coronary angiography (e.g., claustrophobia, contrast agent allergy); (4) Severe liver or kidney dysfunction; (5) Severe coagulation disorders or hemorrhagic diseases.

Observation indicators

Patient data, including general and clinical information, were collected. Venous blood was drawn upon admission to measure initial myocardial enzyme levels, including Lactate Dehydrogenase, Creatine Kinase, Creatine Kinase-MB Isoenzyme, and High-Sensitivity Troponin T (HS-TnT). These myocardial enzyme levels were measured every 24 h, with the peak values of each indicator recorded. Additionally, N-terminal pro b-type natriuretic peptide (NT-proBNP) levels were assessed every 24 h, with the highest value being recorded as the peak NT-proBNP level. This study adheres to the principles of the 1975 Declaration of Helsinki and has received approval from the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (Approval No. XYFY2023-KL317-01).

SYNTAX score calculation

The SYNTAX Score (SS) for each patient was retrospectively calculated based on the recommended SS algorithm. This involved scoring all coronary artery lesions with a diameter stenosis greater than 50% and vessels with a diameter larger than 1.5 mm [21]. The calculation was performed using the publicly accessible, web-based scoring calculator at http://www.syntaxscore.com.

CMR examination and grouping criteria

CMR imaging was performed within the first week post-PCI using a 3.0-T scanner (Ingenia 3.0T, Philips, Netherlands). Patients were placed in a supine position, and images were obtained using a digital stream (dS) phased-array surface coil and an integrated dS posterior spinal matrix coil during breath-hold. After the administration of a gadolinium contrast agent (0.1 mmol/kg), cine images covering the left ventricular short axis (8–10 slices) were acquired. Late Gadolinium Enhancement (LGE) images were obtained 10–15 min after contrast administration. Imaging parameters included a slice thickness of 7 mm, echo time (TE) of 1.4 ms, repetition time (TR) of 2.8 ms, and a field of view (FoV) of 300 mm × 300 mm.

In Late Gadolinium Enhancement CMR (LGE-CMR), contrast agent washout is utilized to outline the areas of MVO. T2-weighted cardiac MRI highlights the tissue characteristics of myocardium and blood. On T2*-weighted CMR imaging, a low signal core within high signal edematous myocardium, identified as lesions with T2* values less than 20ms, is considered indicative of IMH. This appearance is attributed to the paramagnetic effects of hemoglobin degradation products [22]. Patients were categorized based on the presence or absence of IMH detected by CMR into groups with IMH and without IMH.

Statistical methods

Statistical analyses in this study were performed using R software, version 4.2.2. For normally distributed quantitative data, means ± standard deviations were used for representation, with group comparisons conducted using the paired t-test. For non-normally distributed quantitative data, medians (interquartile range) were presented, and the Wilcoxon rank-sum test was applied for comparisons between groups. Categorical variables were compared between groups using the Chi-square test. Univariate and multivariate logistic regression analyses were employed to construct the nomogram model. The predictive ability of the model was assessed using ROC curve analysis, with the predictive value compared based on the area under the ROC curve. Calibration curves and decision curve analysis were generated to evaluate the consistency and accuracy of the model.

Results

Clinical data

The flowchart for the selection of AMI patients is depicted in Fig. 1. A total of 216 AMI patients were included in this study and randomly divided into a training set and a validation set in a 7:3 ratio. Based on the presence or absence of IMH as indicated by CMR, patients were classified into the IMH group (109 patients) and the non-IMH group (107 patients). Significant statistical differences were observed between the two groups in terms of heart rate, presence of ST-segment elevation myocardial infarction, culprit vessel, symptom onset to reperfusion time, C-reactive protein, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, creatine kinase, creatine kinase-MB isoenzyme, HS-TnT, NT-proBNP, and SS (Table 1). Representative examples of obtained CMR and arteriographic results are illustrated in Fig. 2. Table 2 presents a comparison of general and laboratory data between the training and validation sets, showing no statistical differences between the two groups.

Fig. 1.

Fig. 1

Flowchart

Table 1.

Comparison of general and clinical data between the two patient groups

Non-IMH group IMH group Statistical value P value
N = 107 N = 109
Age 54.9 ± 12.1 54.5 ± 11.8 t = 0.258 0.796
Gender X2 = 0.201 0.654
 Male 91 (85.0%) 95 (87.2%)
 Female 16 (15.0%) 14 (12.8%)
BMI (kg/m2, x ± s) 25.5 ± 3.04 26.0 ± 3.22 t=-1.109 0.268
Heart rate 77.9 ± 11.9 81.7 ± 12.3 t=-2.320 0.021
Systolic blood pressure (mmHg) 125 [112;140] 120 [111;133] Z= -1.342 0.180
Diastolic blood pressure (mmHg, x ± s) 79.4 ± 14.0 81.1 ± 13.4 t=-0.915 0.361
Medical history
Hypertension (Classification) X2 = 4.471 0.215
 0 60 (56.1%) 57 (52.3%)
 1 9 (8.41%) 4 (3.67%)
 2 13 (12.1%) 11 (10.1%)
 3 25 (23.4%) 37 (33.9%)
Smoking history X2 = 0.690 0.406
 No 46 (43.0%) 53 (48.6%)
 Yes 61 (57.0%) 56 (51.4%)
Dyslipidemia X2 = 0.155 0.693
 No 59 (55.1%) 63 (57.8%)
 Yes 48 (44.9%) 46 (42.2%)
Diabetes X2 = 1.093 0.296
 No 85 (79.4%) 80 (73.4%)
 Yes 22 (20.6%) 29 (26.6%)
History of drug use
Clopidogrel X2 = 0.004 0.947
 No 86 (80.4%) 88 (80.7%)
 Yes 21 (19.6%) 21 (19.3%)
Beta-blocker X2 = 0.690 0.406
 No 61 (57.0%) 56 (51.4%)
 Yes 46 (43.0%) 53 (48.6%)
ACEI/ARB X2 = 0.323 0.569
 No 63 (58.9%) 60 (55.0%)
 Yes 44 (41.1%) 49 (45.0%)
Clinical data
Killip classification X2 < 0.001 1.000
 I 99 (92.5%) 101 (92.7%)
 II/III/IV 8 (7.48%) 8 (7.34%)
ECG X2 = 5.925 0.015
 STEMI 78 (72.9%) 94 (86.2%)
 NSTEMI 29 (27.1%) 15 (13.8%)
Criminal vessel X2 = 16.153 < 0.001
 LAD 42 (39.3%) 71 (65.1%)
 LCX 19 (17.8%) 16 (14.7%)
 RCA 46 (43.0%) 22 (20.2%)
Time from symptom onset to reperfusion (min) 360 [180;720] 240 [180;420] Z= -2.35 0.019
GLU (mmol/L) * 5.69 [5.01;6.99] 6.06 [5.05;8.32] Z= -1.422 0.155
HbA1c (%) 5.90 [5.60;6.65] 5.90 [5.60;6.90] Z= -0.387 0.699
CRP (mg/L) 19.5 [8.10;42.3] 39.1 [18.10;68.4] Z= -3.945 < 0.001
PLT / LYM 89.1 [72.3;106] 87.0 [72.7;109] Z= -0.016 0.987
AST (U/L) 119 [62.5;176] 311 [215;508] Z= -8.294 < 0.001
ALT (U/L) 39.0 [29.0;52.5] 56.0 [39.0;75.0] Z= -5.335 < 0.001
LDH (×102U/L) 5.89 [3.42;8.31] 11.7 [7.64;19.50] Z= -7.538 < 0.001
CK (×103U/L) 1.00 [0.52;1.54] 3.84 [1.60;6.66] Z= -8.247 < 0.001
CKMB (ng/ml) 72.2 [26.4;136] 254 [130;300] Z= -7.336 < 0.001
HS-TnT (×103ng/L) 1.90 [1.11;3.22] 6.72 [4.10;9.75] Z= -9.372 < 0.001
NT-proBNP (×103pg/L) 0.87 [0.47;1.44] 1.33 [0.70;2.10] Z= -3.048 0.002
SS (×10) 1.80 [1.30;2.12] 2.65 [2.25;3.25] Z= -7.568 < 0.001

Fig. 2.

Fig. 2

Two illustrative cases of CMR imaging and arteriography are presented. In the first case, without IMH (Panels A–D): (A) T2-weighted CMR reveals infarct zone hyperintensity (red arrowheads); (B) T2*-weighted CMR shows reduced infarct zone affinity; (C) LGE CMR highlights the extensive infarction (red arrowheads); (D) CAG reveals complete occlusion of the mid left circumflex artery (LCX). In the second case, featuring IMH (Panels E–H): (E) T2-weighted CMR identifies IMH as a hypointense core (red line circles) within a hyperintense zone (yellow line circles); (F) T2*-weighted CMR more clearly delineates the IMH, appearing as a dark area; (G) LGE CMR shows a hypointense core (red line circles) within a hyperintense zone (yellow line circles), indicative of microvascular injury; (H) CAG shows total occlusion of the left anterior descending artery (LAD)

Table 2.

General and clinical data of patients in the training and validation sets

Training set Verification set Statistical value P value
N = 151 N = 65
Age 55.0 [47.0;64.0] 56.0 [46.0;64.0] Z= -0.174 0.868
Gender X2 < 0.001 1.000
 Male 130 (86.1%) 56 (86.2%)
 Female 21 (13.9%) 9 (13.8%)
BMI (kg/m2, x ± s) 25.7 [23.9;27.8] 25.0 [23.4;27.5] Z= -1.238 0.190
Heart Rate 79.7 ± 12.5 80.0 ± 11.6 t = 0.207 0.837
Systolic blood pressure (mmHg) 124 [112;137] 123 [113;136] Z= -1.342 0.996
Diastolic blood pressure (mmHg, x ± s) 80.1 ± 13.8 80.4 ± 13.5 t = 0.162 0.872
Medical history
Hypertension (Classification) X2 = 2.141 0.544
 0 78 (51.7%) 39 (60.0%)
 1 11 (7.28%)  2 (3.08%)
 2 17 (11.3%) 7 (10.8%)
 3 45 (29.8%) 17 (26.2%)
Smoking history X2 = 0.004 1.000
 No 69 (45.7%) 30 (46.2%)
 Yes 82 (54.3%) 35 (53.8%)
Dyslipidemia X2 = 0.468 0.494
 No 83 (55.0%) 39 (60.0%)
 Yes 68 (45.0%) 26 (40.0%)
Diabetes X2 = 0.221 0.638
 No 114 (75.5%) 51 (78.5%)
 Yes 37 (24.5%) 14 (21.5%)
History of drug use
Clopidogrel X2 = 0.783 0.376
 No 124 (82.1%) 50 (76.9%)
 Yes 27 (17.9%) 15 (23.1%)
Beta-blocker X2 = 0.056 0.814
 No 81 (53.6%) 36 (55.4%)
 Yes 70 (46.4%) 29 (44.6%)
ACEI/ARB X2 = 0.354 0.552
 No 84 (55.6%) 39 (60.0%)
 Yes 67 (44.4%) 26 (40.0%)
Clinical data
Killip classification X2 < 0.001 1.000
 I 140 (92.7%) 60 (92.3%)
 II/III/IV 11 (7.28%) 5 (7.69%)
ECG X2 = 1.917 0.166
 STEMI 124 (82.1%) 48 (73.8%)
 NSTEMI 27 (17.9%) 17 (26.2%)
Criminal vessel X2 = 5.225 0.073
 LAD 86 (57.0%) 27 (41.5%)
 LCX 20 (13.2%) 15 (23.1%)
 RCA 45 (29.8%) 23 (35.4%)
Time from symptom onset to reperfusion (min) 300 [180;540] 300 [210;720] Z= -2.350 0.208
GLU (mmol/L) * 5.89 [5.10;7.32] 5.71 [4.94;7.09] Z= -1.422 0.246
HbA1c (%) 6.00 [5.70;6.90] 5.80 [5.60;6.50] Z= -0.387 0.115
CRP (mg/L) 27.5 [11.7;60.6] 27.6 [10.6;60.5] Z= -3.945 0.974
PLT / LYM 88.3 [70.2;106] 88.1 [75.2;108] Z= -0.016 0.562
AST (U/L) 191 [99.5;330] 191 [100;408] Z= -8.294 0.917
ALT (U/L) 45.0 [33.0;61.5] 51.0 [35.0;68.0] Z= -5.335 0.488
LDH (×102U/L) 7.84 [4.99;12.0] 8.93 [4.60;14.1] Z= -7.538 0.428
CK (×103U/L) 1.53 [0.78;3.93] 1.60 [0.97;3.70] Z= -8.247 0.812
CKMB (ng/ml) 124 [53.8;272] 189 [64.3;264] Z= -7.336 0.646
HS-TnT (×103ng/L) 3.59 [1.68;6.88] 3.75 [1.75;7.29] Z= -9.372 0.981
NT-proBNP (×103pg/L) 1.12 [0.65;1.89] 1.01 [0.45;1.91] Z= -3.048 0.294
SS (×10) * 2.25 [1.50;2.85] 2.15 [1.60;2.80] Z= -7.568 0.759

Univariate and multivariate logistic regression analysis of independent predictors for IMH post-PCI in AMI patients

In Table 3, the results of the univariate logistic regression analysis showed significant statistical differences between the two groups in baseline heart rate, diastolic blood pressure, ST-segment elevation, culprit vessel, symptom onset to reperfusion time, C-reactive protein, aspartate aminotransferase, myocardial enzymes, troponin, and SS. Variables with P < 0.05 in the univariate analysis were included in the multivariate logistic regression analysis. The results identified HS-TnT and SS as independent risk factors for the occurrence of IMH post-PCI in AMI patients (both P values < 0.05), with cut-off values of 3.61 and 2.23, respectively. Table 3 presents the OR, 95% confidence intervals, and P values for both the univariate and multivariate logistic regression analyses.

Table 3.

Logistic regression analysis of independent predictors for IMH post-PCI in AMI patients

Clinical factors Univariate logistic regression Multivariate logistic regression
OR 95%CI P OR 95%CI P
Age 0.99 0.97–1.02 0.716
Gender 1.21 0.48–3.04 0.690
BMI 1.07 0.96–1.19 0.199
Heat rate 1.03 1.01–1.06 0.016 1.01 0.97–1.06 0.524
Systolic blood pressure 1.00 0.99–1.02 0.816
Diastolic blood pressure 1.02 1.00-1.05 0.047 1.02 0.98–1.06 0.379
Hypertension (Classification): 0 VS 1 0.39 0.10–1.60 0.193
Hypertension (Classification): 0 VS 2 0.94 0.33–2.68 0.901
Hypertension (Classification): 0 VS 3 1.91 0.90–4.06 0.093
Smoking history 0.56 0.29–1.07 0.081
Hyperlipidemia 0.89 0.47–1.68 0.713
Diabetes history 1.76 0.82–3.77 0.144
Clopidogrel 1.01 0.44–2.32 0.982
Beta-blocker 1.35 0.71–2.58 0.354
ACEI/ARB 1.29 0.68–2.46 0.434
Killip classification 0.76 0.22–2.62 0.670
ECG 0.32 0.13–0.80 0.014 0.59 0.13–2.54 0.485
Criminal vessel: LAD VS LCX 0.44 0.16–1.18 0.101 2.39 0.61–9.86 0.216
Criminal vessel: LAD VS RCA 0.44 0.21–0.91 0.027 0.73 0.23–2.27 0.585
Time from symptom onset to reperfusion (min) 1.00 1.00–1.00 0.010 1.00 1.00–1.00 0.344
GLU(mmol/L) * 1.10 0.99–1.22 0.071
HbA1c 1.08 0.89–1.30 0.432
CRP 1.01 1.00-1.02 0.039 1.01 1.00-1.02 0.221
PLT / LYM 1.00 0.99–1.01 0.739
AST 1.01 1.00-1.01 < 0.001 0.99 0.99-1.00 0.193
ALT 1.00 1.00–1.00 0.739
LDH 1.23 1.13–1.34 < 0.001 1.03 0.90–1.20 0.651
CK 2.04 1.56–2.68 < 0.001 1.52 1.00-2.51 0.078
CKMB 1.01 1.01–1.02 < 0.001 1.00 0.99–1.01 0.759
HS-TnT 1.87 1.53–2.28 < 0.001 1.61 1.21–2.25 0.003
NT-proBNP 1.23 0.98–1.54 0.069
SS 4.26 2.53–7.18 < 0.001 2.54 1.42–4.90 0.003

Construction of the nomogram

To better address clinical needs, a predictive model for assessing the occurrence of IMH post-PCI in patients with AMI was developed. This model was based on the independent predictors identified through multivariate logistic regression and their corresponding coefficients. The formula of the model is: log(p/(1-p)) = -4.22 + 0.52HS-TnT + 0.97SS. A nomogram was then created based on this predictive model (Fig. 3). Using this formula, we can accurately calculate the risk of IMH in patients with AMI post- PCI based on their HS-TnT and SS.

Fig. 3.

Fig. 3

Construction of nomogram for predicting the occurrence of IMH post-PCI in AMI patients

Accuracy assessment of the nomogram

To verify the accuracy of the constructed nomogram model, ROC curves were plotted. In the training set, the AUC of the nomogram model was 0.893 (95% CI: 0.840–0.946). In the validation set, the AUC was 0.910 (95% CI: 0.823–0.970), indicating that the model exhibits good accuracy in both the training and validation sets (Fig. 4). Additionally, calibration curves were drawn for both the training and validation sets (Fig. 5) to assess the model’s accuracy. The results showed that the predicted probabilities of the nomogram closely match the actual probabilities, further indicating the model’s reliability. The Hosmer-Lemeshow goodness-of-fit test showed no significant difference (X2 = 3.68, P = 0.885), affirming the model’s fit. Finally, decision curve analysis was used to compare the predictive capabilities of the nomogram with the independent risk factors. The decision curve indicated that the nomogram model’s predictions for post-PCI IMH in AMI patients were superior to those based on independent risk factors alone (Fig. 6).

Fig. 4.

Fig. 4

ROC curves of the nomogram model on the training set (A) and validation set (B)

Fig. 5.

Fig. 5

Calibration curves of the nomogram model on the training set (A) and validation set (B)

Fig. 6.

Fig. 6

Decision curves of the nomogram model on the training set (A) and validation set (B)

Discussion

AMI represents the most severe pathophysiological state of coronary heart disease, posing an immediate threat to patient survival [23]. Presently, PCI combined with antithrombotic therapy is the primary method for re-establishing coronary circulation in AMI patients [24]. However, some patients experience myocardial hemorrhage due to severe ischemic injury to the myocardium during reperfusion and MVO post-PCI, leading to vascular integrity disruption and extravasation of red blood cells [25]. In a clinical study conducted by Noé Corpataux et al. [26] on AMI patients post-PCI, the overall incidence of IMH was found to be as high as 43%. Therefore, accurate prediction of IMH post-PCI is of significant importance for the prognosis of AMI patients.

CMR is a useful non-invasive technique for determining the presence of MVO and IMH)in patients following reperfused AMI. Currently, dark-blood T2*-based CMR and bright-blood T2*-weighted CMR are becoming interchangeably used for the detection of IMH, enabling effective diagnosis of IMH [27]. Interestingly, studies have shown that positron emission tomography/magnetic resonance imaging (PET/MRI) is gradually providing new insights into the molecular mechanisms of the healing process post-myocardial infarction. In the context of myocardial infarction, PET/MRI can provide important biomarker information that reveals key processes such as myocardial metabolic status, inflammatory responses, apoptosis, and angiogenesis during the repair process [28]. Through this multimodal imaging approach, researchers and clinicians can gain a comprehensive view of the healing process after myocardial infarction, which is of significant importance for optimizing treatment strategies, assessing therapeutic effects, and predicting patient prognosis.

The Syntax Score (SS) is an established tool for assessing the complexity of coronary artery disease (CAD), particularly in patients with multivessel coronary artery disease and/or left main coronary artery lesions [29, 30]. The SS is primarily based on the location, type, and number of coronary artery lesions, providing robust theoretical support for the choice between PCI and Coronary Artery Bypass Grafting (CABG) [31, 32]. Studies have demonstrated that SS can predict the prognosis of patients undergoing PCI or CABG, offering a significant theoretical basis for evaluating the severity and prognosis of coronary heart disease [33]. High-sensitivity Troponin T (HS-TnT) is a highly specific biomarker for myocardial injury assessment [34]. Troponin testing, as the preferred and essential condition for diagnosing myocardial infarction, reduces the missed diagnosis rate of acute coronary syndrome and myocardial infarction and is widely used in clinical settings [35, 36]. Our study retrospectively analyzed the clinical indicator levels in patients with AMI post-PCI and calculated the corresponding SS based on coronary angiography, using Cardiac Magnetic Resonance (CMR) as the gold standard for grouping [37]. We found that HS-TnT levels and SS are independent risk factors for Intramyocardial Hemorrhage (IMH) post-PCI in AMI patients. Studies indicate that reperfusion can lead to necrosis within the epicardial wavefront, thereby elevating HS-TnT levels. We believe that compared to traditional troponins, HS-TnT offers higher sensitivity and specificity, allowing for earlier and more accurate detection of myocardial cell damage, which is closely related to intramyocardial hemorrhage. In this study, we also observed that patients with increased SS are more prone to intramyocardial hemorrhage. This susceptibility may be linked to the heavier burden of coronary atherosclerosis in patients with higher SS, where the revascularization and stent placement lead to mechanical disruption of the compromised vessels. A predictive model for IMH was constructed based on HS-TnT levels and SS. The results indicated that patients with IMH had higher HS-TnT levels and SS compared to those without IMH (Odds Ratio = 1.61/2.54, 95% Confidence Interval: 1.21–2.25/1.42–4.90, P = 0.003/0.003), consistent with findings by Liu et al. that troponin peak levels post-direct PCI are higher in patients with bleeding (P < 0.01) [38]. Although the AUC value of SS in ROC analysis is not as significant as HS-TnT levels, combining these two indicators through a nomogram model yields a predictive power greater than their independent predictive values. By calculating the scores of AMI patients post-PCI using the nomogram model, we can identify patients at high risk of IMH early, allowing for timely and appropriate clinical intervention, which is crucial for improving patient outcomes.

However, this study has several limitations: (1) It is a single-center retrospective study with a relatively small sample size. (2) There was no follow-up on patient outcomes and major adverse cardiac events (MACE), leading to a lack of systematic and comprehensive analysis of the prognosis of patients with IMH. (3) In this study, the assessment of SS was conducted by experienced professionals in a single center, and its predictive value in everyday clinical practice may require further evaluation through multicenter, double-blind studies.

Conclusion

In summary, the nomogram model constructed using HS-TnT and SS can accurately predict the risk of IMH post-PCI in patients with AMI. This model can guide further diagnosis and treatment post-PCI in AMI patients, contributing to improved patient prognosis.

Acknowledgements

We thank all patients for participating in this study.

Abbreviations

ECG

Electrocardiogram

STEMI

ST-Segment Elevation Myocardial Infarction

NSTEMI

Non-ST-Segment Elevation Myocardial Infarction

LAD

Left Anterior Descending artery

LCX

Left Circumflex artery

RCA

Right Coronary Artery

GLU

Glucose

HbA1c

Hemoglobin A1c

CRP

C-Reactive Protein

PLT

Platelets

LYM

Lymphocytes

AST

Aspartate Aminotransferase

ALT

Alanine Aminotransferase

LDH

Lactate Dehydrogenase

CK

Creatine Kinase

CKMB

Creatine Kinase-MB

HS-TnT

High-Sensitivity Troponin T

NT-proBNP

N-Terminal pro b-type Natriuretic Peptide

SS

SYNTAX Score

Author contributions

Y.Y. was primarily responsible for the design of the article, data collection, and manuscript writing; D.X. was in charge of data analysis; Y.D., M.Y., K.L., Y.M., and C.H. were responsible for revising the manuscript; S.H. and K.X. provided guidance for the manuscript writing and finalized the manuscript.

Funding

This study is supported by the grants from the National Natural Science Foundation of China (82271980), Key Research and Development Project of Xuzhou (KC22124), Project supported by the Affiliated Hospital of Xuzhou Medical University (2023ZY03) and the Jiangsu Postgraduates’ Research and Practice Innovation Project (KYCX22_2938).

Data availability

The data analyzed in this study can be obtained from the corresponding authors upon request.

Declarations

Ethics approval and consent to participate

This study adheres to the principles of the 1975 Declaration of Helsinki and has received approval from the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (Approval No. XYFY2023-KL317-01). All participants provided written informed consent before the start of the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yin-shuang Yang and De-yang Xi contributed equally to this work.

Contributor Information

Shu-guang Han, Email: hsgxyfy@163.com.

Kai Xu, Email: xukai_paper@163.com.

References

  • 1.Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med. 2017;376(21):2053–64. doi: 10.1056/NEJMra1606915. [DOI] [PubMed] [Google Scholar]
  • 2.Gong FF, et al. Mechanical complications of Acute myocardial infarction: a review. JAMA Cardiol. 2021;6(3):341–9. doi: 10.1001/jamacardio.2020.3690. [DOI] [PubMed] [Google Scholar]
  • 3.Mann DL, Nicolas J, Claggett B, et al. Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI. J Am Coll Cardiol. 2024;83(9):904–14. doi: 10.1016/j.jacc.2024.01.002. [DOI] [PubMed] [Google Scholar]
  • 4.Mozaffarian D, et al. Heart Disease and Stroke Statistics-2016 update: a Report from the American Heart Association. Circulation. 2016;133(4):e38–360. doi: 10.1161/CIR.0000000000000350. [DOI] [PubMed] [Google Scholar]
  • 5.Murray CJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145–91. doi: 10.1016/S0140-6736(15)61340-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Byrne I, Rossello RA, Coughlan X. 2023 ESC guidelines for the management of acute coronary syndromes [published correction appears in Eur Heart J. 2024] Eur Heart J. 2023;44(38):3720–826. doi: 10.1093/eurheartj/ehad191. [DOI] [PubMed] [Google Scholar]
  • 7.Konijnenberg L, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovasc Res. 2020;116(4):787–805. doi: 10.1093/cvr/cvz301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Del BM, et al. Coronary microvascular dysfunction across the Spectrum of Cardiovascular diseases: JACC State-of-the-art review. J Am Coll Cardiol. 2021;78(13):1352–71. doi: 10.1016/j.jacc.2021.07.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020;17(12):773–89. doi: 10.1038/s41569-020-0403-y. [DOI] [PubMed] [Google Scholar]
  • 10.Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition ofmyocardial infarction (2018) [Fourth Universal definition of myocardial infarction (2018)] Kardiol Pol. 2018;76(10):1383–415. doi: 10.5603/KP.2018.0203. [DOI] [PubMed] [Google Scholar]
  • 11.Myerson SG. CMR in evaluating Valvular Heart Disease: diagnosis, severity, and outcomes. JACC Cardiovasc Imaging. 2021;14(10):2020–32. doi: 10.1016/j.jcmg.2020.09.029. [DOI] [PubMed] [Google Scholar]
  • 12.Beijnink C, et al. Cardiac MRI to visualize myocardial damage after ST-Segment Elevation myocardial infarction: a review of its histologic validation. Radiology. 2021;301(1):4–18. doi: 10.1148/radiol.2021204265. [DOI] [PubMed] [Google Scholar]
  • 13.Yadav M, et al. Prediction of coronary risk by SYNTAX and derived scores: synergy between percutaneous coronary intervention with taxus and cardiac surgery. J Am Coll Cardiol. 2013;62(14):1219–30. doi: 10.1016/j.jacc.2013.06.047. [DOI] [PubMed] [Google Scholar]
  • 14.Bundhun PK, Bhurtu A, Huang F. Worse clinical outcomes following percutaneous coronary intervention with a high SYNTAX score: a systematic review and meta-analysis. Med (Baltim) 2017;96(24):e7140. doi: 10.1097/MD.0000000000007140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Gao G, et al. Prognostic value of the SYNTAX score on myocardial injury and salvage in STEMI patients after primary percutaneous coronary intervention: a single-center retrospective observational study. BMC Cardiovasc Disord. 2021;21(1):591. doi: 10.1186/s12872-021-02395-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Homorodean C, et al. New predictors of early and late outcomes after primary percutaneous coronary intervention in patients with ST-Segment Elevation Myocardial Infarction and Unprotected Left Main Coronary Artery Culprit Lesion. J Interv Cardiol. 2019;2019:p8238972. doi: 10.1155/2019/8238972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Elgendy IY, et al. Complete or culprit-only revascularization for patients with Multivessel Coronary Artery Disease undergoing percutaneous coronary intervention: a pairwise and Network Meta-Analysis of Randomized trials. JACC Cardiovasc Interv. 2017;10(4):315–24. doi: 10.1016/j.jcin.2016.11.047. [DOI] [PubMed] [Google Scholar]
  • 18.Gragnano F, Heg D, Franzone A, et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. Eur Heart J Cardiovasc Pharmacother. 2022;8(1):28–38. doi: 10.1093/ehjcvp/pvaa106. [DOI] [PubMed] [Google Scholar]
  • 19.Xiao Y, Fu X, Wang Y, Wu Y, Wang W, Zhang Q. Development and Validation of Risk Nomogram Model Predicting Coronary Microvascular obstruction in patients with ST-Segment Elevation myocardial infarction (STEMI) undergoing primary percutaneous catheterization. Med Sci Monit. 2019;25:5864–77. doi: 10.12659/MSM.915960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Fang C et al. Dec. Construction and evaluation of nomogram model for individualized prediction of risk of major adverse cardiovascular events during hospitalization after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Frontiers in cardiovascular medicine vol. 9 1050785. 21 2022, 10.3389/fcvm.2022.1050785. [DOI] [PMC free article] [PubMed]
  • 21.Sianos G, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219–27. [PubMed] [Google Scholar]
  • 22.Betgem RP, et al. Intramyocardial haemorrhage after acute myocardial infarction. Nat Rev Cardiol. 2015;12(3):156–67. doi: 10.1038/nrcardio.2014.188. [DOI] [PubMed] [Google Scholar]
  • 23.Samsky MD, et al. Cardiogenic shock after Acute myocardial infarction: a review. JAMA. 2021;326(18):1840–50. doi: 10.1001/jama.2021.18323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of Acute Coronary syndromes: a review. JAMA. 2022;327(7):662–75. doi: 10.1001/jama.2022.0358. [DOI] [PubMed] [Google Scholar]
  • 25.Rifkind JM, Mohanty JG, Nagababu E. The pathophysiology of extracellular hemoglobin associated with enhanced oxidative reactions. Front Physiol. 2014;5:500. doi: 10.3389/fphys.2014.00500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Carrick D et al. Temporal evolution of myocardial hemorrhage and edema in patients after Acute ST-Segment Elevation myocardial infarction: pathophysiological insights and clinical implications. J Am Heart Assoc, 2016. 5(2). [DOI] [PMC free article] [PubMed]
  • 27.Guan X, Chen Y, Yang HJ et al. Assessment of intramyocardial hemorrhage with dark-blood T2*-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2021;23(1):88. Published 2021 Jul 15. 10.1186/s12968-021-00787-4. [DOI] [PMC free article] [PubMed]
  • 28.Calvieri C, Masselli G, Monti R, Spreca M, Gualdi GF, Fedele F. Intramyocardial hemorrhage: an enigma for cardiac MRI? Biomed Res Int. 2015;2015:859073. doi: 10.1155/2015/859073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Nagarajarao HS, et al. Current Use and trends in Unprotected Left Main Coronary Artery Percutaneous intervention. Curr Cardiol Rep. 2020;22(4):16. doi: 10.1007/s11886-020-1268-8. [DOI] [PubMed] [Google Scholar]
  • 30.Freemantle N, Pagano D. Concerns with the new SYNTAX score. Lancet. 2021;397(10276):795. doi: 10.1016/S0140-6736(21)00223-3. [DOI] [PubMed] [Google Scholar]
  • 31.Neumann FJ, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. doi: 10.1093/eurheartj/ehy394. [DOI] [PubMed] [Google Scholar]
  • 32.Cavalcante R, et al. Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. Eur Heart J. 2017;38(25):1969–77. doi: 10.1093/eurheartj/ehx138. [DOI] [PubMed] [Google Scholar]
  • 33.Andreini D, et al. The usefulness of cardiac CT integrated with FFRCT for planning myocardial revascularization in complex coronary artery disease: a lesson from SYNTAX studies. Cardiovasc Diagn Ther. 2020;10(6):2036–47. doi: 10.21037/cdt.2019.11.07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Cortés M, et al. High-sensitivity troponin T for the Risk Assessment of patients with Acute Atrial Fibrillation. Curr Probl Cardiol. 2022;47(11):101079. doi: 10.1016/j.cpcardiol.2021.101079. [DOI] [PubMed] [Google Scholar]
  • 35.Kampmann J et al. Troponin cut-offs for Acute myocardial infarction in patients with impaired renal Function-A systematic review and Meta-analysis. Diagnostics (Basel), 2022. 12(2). [DOI] [PMC free article] [PubMed]
  • 36.Michailovich CA. Diagnostic role and methods of detection of Cardiac troponins: an opinion from historical and current points of View. Curr Cardiol Rev. 2023;19(1):e100622205865. doi: 10.2174/1573403X18666220610164946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Andò G, Capodanno D. Radial Access reduces mortality in patients with Acute Coronary syndromes: results from an updated Trial Sequential Analysis of Randomized trials. JACC Cardiovasc Interv. 2016;9(7):660–70. doi: 10.1016/j.jcin.2015.12.008. [DOI] [PubMed] [Google Scholar]
  • 38.Liu T, et al. Intramyocardial Hemorrhage and the Wave Front of Reperfusion Injury compromising myocardial salvage. J Am Coll Cardiol. 2022;79(1):35–48. doi: 10.1016/j.jacc.2021.10.034. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data analyzed in this study can be obtained from the corresponding authors upon request.


Articles from BMC Cardiovascular Disorders are provided here courtesy of BMC

RESOURCES